Ou, Li

rAAV immunogenicity, toxicity, and durability in 255 clinical trials: A meta-analysis

Shen, W., Liu, S., & Ou, L. (2022) · Frontiers in Immunology

Virus-based gene therapy researchRNA Interference and Gene Delivery

Cited by 173

Dose-dependent prevention of metabolic and neurologic disease in murine MPS II by ZFN-mediated in vivo genome editing

Laoharawee, K., DeKelver, R. C., Podetz-Pedersen, K. M., Rohde, M., Sproul, S., Nguyen, H.-O., Nguyen, T., St. Martin, S. J., Ou, L., Tom, S., et al. (2018) · Molecular Therapy

Lysosomal Storage Disorders ResearchVirus-based gene therapy research

Cited by 125

ZFN-mediated in vivo genome editing corrects murine hurler syndrome

Ou, L., DeKelver, R. C., Rohde, M., Tom, S., Radeke, R., St. Martin, S. J., Santiago, Y., Sproul, S., Przybilla, M. J., Koniar, B. L., et al. (2019) · Molecular Therapy

Lysosomal Storage Disorders ResearchVirus-based gene therapy research

Cited by 84

A versatile toolkit for overcoming AAV immunity

Li, X., Wei, X., Lin, J., & Ou, L. (2022) · Frontiers in Immunology

Virus-based gene therapy researchRNA Interference and Gene Delivery

Cited by 57

A highly efficacious PS gene editing system corrects metabolic and neurological complications of mucopolysaccharidosis type I

Ou, L., Przybilla, M. J., Ahlat, O., Kim, S., Overn, P., Jarnes, J., O’Sullivan, M. G., & Whitley, C. B. (2020) · Molecular Therapy

Lysosomal Storage Disorders ResearchVirus-based gene therapy research

Cited by 56

A novel gene editing system to treat both Tay–Sachs and sandhoff diseases

Ou, L., Przybilla, M. J., Tăbăran, A.-F., Overn, P., O’Sullivan, M. G., Jiang, X., Sidhu, R., Kell, P. J., Ory, D. S., & Whitley, C. B. (2020) · Gene Therapy

Lysosomal Storage Disorders ResearchVirus-based gene therapy research

Cited by 52